Quantum Biopharma Announces Completion of Dosing in 180-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-21-302 (Lucid-MS)
12/23/2025 08:00 AM • Quantum BioPharma announced completion of oral dosing in 180-day repeated dose toxicity and toxicokinetic studies for Lucid-21-302 (Lucid-MS), a first-in-class treatment candidate for multiple sclerosis. The studies will support the company's Investigational New Drug (IND) application with the US FDA and inform the design of a Phase 2 trial. Lucid-MS is designed to prevent myelin degradation and disease progression in MS patients.
QNTM - Completion of critical 180-day toxicity studies represents significant progress in the drug development pipeline. These studies are essential regulatory milestones that advance the company closer to FDA IND approval and Phase 2 clinical trials for a first-in-class MS treatment, demonstrating operational execution and de-risking of the development program.